An Open-label, Multi-center, Roll-over Study to Assess Long Term Safety in Patients With Endogenous Cushing's Syndrome Who Have Completed a Prior Novartis-sponsored Osilodrostat (LCI699) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Osilodrostat
Latest Information Update: 31 Jul 2020
At a glance
- Drugs Osilodrostat (Primary)
- Indications Cushing syndrome
- Focus Adverse reactions
- Sponsors Novartis; Novartis Healthcare; Novartis Pharmaceuticals
- 21 Apr 2020 Planned End Date changed from 1 Nov 2023 to 5 Oct 2023.
- 30 Jun 2019 Planned End Date changed from 24 Oct 2023 to 1 Nov 2023.
- 14 Dec 2018 Planned End Date changed from 27 Sep 2023 to 24 Oct 2023.